{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:46:50Z","timestamp":1788580010209,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["361"],"award-info":[{"award-number":["361"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004001","name":"Guizhou Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["QKHPTRC-CXTD [2022] 012"],"award-info":[{"award-number":["QKHPTRC-CXTD [2022] 012"]}],"id":[{"id":"10.13039\/501100004001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmc.2026.118669","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:28:39Z","timestamp":1776871719000},"page":"118669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Exploration of a novel series of isoindolinone-based hydroxamate derivatives: Design, synthesis, and evaluation of anticancer activity"],"prefix":"10.1016","volume":"138","author":[{"given":"Xizheng","family":"Quan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudie","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118669_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115938","article-title":"Dual inhibitors of HDAC and other epigenetic regulators: a novel strategy for cancer treatment","volume":"263","author":"Shirbhate","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108700","article-title":"Hydroxamic acid hybrids as histone deacetylase inhibitors for cancer therapy: an update (2022 to date)","volume":"163","author":"Cheng","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.bmc.2026.118669_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175216","article-title":"The emerging roles of HDACs and their therapeutic implications in cancer","volume":"931","author":"Hai","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bmc.2026.118669_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1369\/0022155413506582","article-title":"Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer","volume":"62","author":"Parbin","year":"2014","journal-title":"J Histochem Cytochem"},{"issue":"6","key":"10.1016\/j.bmc.2026.118669_bb0030","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.bmc.2026.118669_bb0035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/jcb.21746","article-title":"Histone deacetylases as transducers and targets of nuclear signaling","volume":"104","author":"Walkinshaw","year":"2008","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bmc.2026.118669_bb0040","article-title":"Histone deacetylase complexes: structure, regulation and function","volume":"1879","author":"Asmamaw","year":"2024","journal-title":"BBA-Reviews on Cancer"},{"key":"10.1016\/j.bmc.2026.118669_bb0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-024-00507-5","article-title":"Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives","volume":"13","author":"Pu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.bmc.2026.118669_bb0050","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.ejmech.2010.02.030","article-title":"Inside HDAC with HDAC inhibitors","volume":"45","author":"Bertrand","year":"2010","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0055","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.bmc.2026.118669_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116696","article-title":"Overview of class i HDAC modulators: inhibitors and degraders","volume":"276","author":"Huang","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117185","article-title":"Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: a review","volume":"283","author":"Lv","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/14737140.2025.2452338","article-title":"Anticancer properties of histone deacetylase inhibitors\u2013what is their potential?","volume":"25","author":"Kie\u0142bowski","year":"2025","journal-title":"Expert Review of Anticancer Therapy"},{"key":"10.1016\/j.bmc.2026.118669_bb0075","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s40001-024-02108-8","article-title":"Histone deacetylase inhibitors for leukemia treatment: current status and future directions","volume":"29","author":"Hosseini","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.bmc.2026.118669_bb0080","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","article-title":"Advances in targeting histone deacetylase for treatment of solid tumors","volume":"17","author":"Shi","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2026.118669_bb0085","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s13311-013-0226-1","article-title":"Small molecule inhibitors of zinc-dependent histone deacetylases","volume":"10","author":"Wagner","year":"2013","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.bmc.2026.118669_bb0090","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.bioorg.2016.05.005","article-title":"Inhibitors of histone deacetylase as antitumor agents: a critical review","volume":"67","author":"Manal","year":"2016","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0095","doi-asserted-by":"crossref","first-page":"14171","DOI":"10.1021\/acs.jmedchem.5c01677","article-title":"Advancements in hydrazide-based HDAC inhibitors: a review of recent developments and therapeutic potential","volume":"68","author":"Raucci","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0100","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of hdac inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2026.118669_bb0105","doi-asserted-by":"crossref","first-page":"21843","DOI":"10.1021\/acsomega.1c03628","article-title":"Hydroxamic acid derivatives: from synthetic strategies to medicinal chemistry applications","volume":"6","author":"Citarella","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2026.118669_bb0110","doi-asserted-by":"crossref","first-page":"16480","DOI":"10.1021\/acs.jmedchem.4c01310","article-title":"Development of a first-in-class DNMT1\/HDAC inhibitor with improved therapeutic potential and potentiated antitumor immunity","volume":"67","author":"Chang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0115","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"C. To","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118669_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128846","article-title":"Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: design, synthesis, biological evaluation and modelling studies","volume":"72","author":"Zhu","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118669_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112904","article-title":"Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors","volume":"209","author":"Bass","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0130","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1021\/jm00401a022","article-title":"Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives","volume":"31","author":"Morishita","year":"1988","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108562","article-title":"Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor","volume":"161","author":"Chen","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0140","doi-asserted-by":"crossref","first-page":"16541","DOI":"10.1021\/acs.jmedchem.2c01413","article-title":"Design and synthesis of fibroblast growth factor receptor (FGFR) and histone deacetylase (HDAC) dual inhibitors for the treatment of cancer","volume":"65","author":"Wan","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0145","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1021\/acs.jmedchem.2c01985","article-title":"Design and synthesis of triazole-containing HDAC inhibitors that induce antitumor effects and immune response","volume":"66","author":"Sun","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0150","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1021\/acs.jmedchem.4c03084","article-title":"Design, synthesis, and biological evaluation of novel Fms-like tyrosine kinase 3\/VEGFR2\/histone deacetylase inhibitors for the treatment of acute myeloid leukemia","volume":"68","author":"Tian","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116074","article-title":"Identification of novel aminopyrimidine derivatives for the treatment of mutant NSCLC","volume":"265","author":"Hu","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118669_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.141011","article-title":"Design, synthesis, biological evaluation and molecular docking study of novel quinolone derivatives as potent HDAC1 (histone deacetylase) inhibitors and anticancer agents","volume":"1325","author":"Eskandarpour","year":"2025","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2026.118669_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112643","article-title":"Identification of novel quinoline analogues bearing thiazolidinones as potent kinase inhibitors for the treatment of colorectal cancer","volume":"204","author":"Zhou","year":"2020","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:27:37Z","timestamp":1783132057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"alternative-id":["S0968089626001252"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118669","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploration of a novel series of isoindolinone-based hydroxamate derivatives: Design, synthesis, and evaluation of anticancer activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118669","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118669"}}